Pharsight

Duaklir Pressair generic

Duaklir Pressair is a drug owned by Astrazeneca. It contains the active ingredients Aclidinium Bromide and Formoterol Fumarate. This drug was first authorized for market use on March 29, 2019, and it currently holds a total of 5 drug patents.

When will Duaklir Pressair generic be available?

The generics of Duaklir Pressair are likely to be released after March 13, 2029. This anticipated release date takes into account the expiration of the drug's last patent - US10085974 & US11000517 - on the same date. This might suggest a potential opportunity for a Para IV filing, which could expedite the availability of Duaklir Pressair generic.

Duaklir Pressair uses

Duaklir Pressair is widely used as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The drug's effectiveness is largely due to its two active ingredients: Aclidinium Bromide and Formoterol Fumarate.

Duaklir Pressair patent expiration

Duaklir Pressair has a total of 5 patents. The last patent (US10085974 & US11000517), which is set to expire on March 13, 2029, is likely to dictate the release date for Duaklir Pressair's generic version. Below are the details of the patents:

EPO Oppostions filed on Duaklir Pressair

Duaklir Pressair dosage

Want to ask something?